Sanofi (NASDAQ:SNY – Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 5,290,000 shares, an increase of 25.7% from the December 31st total of 4,210,000 shares. Based on an average daily trading volume, of 2,420,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 0.2% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $60.00.
Read Our Latest Report on Sanofi
Institutional Inflows and Outflows
Sanofi Price Performance
NASDAQ SNY traded up $0.19 on Friday, hitting $54.34. The stock had a trading volume of 3,199,286 shares, compared to its average volume of 2,300,899. The firm has a 50-day moving average of $49.24 and a 200-day moving average of $52.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company has a market capitalization of $137.91 billion, a price-to-earnings ratio of 27.72, a price-to-earnings-growth ratio of 1.21 and a beta of 0.57.
Sanofi (NASDAQ:SNY – Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Equities analysts expect that Sanofi will post 3.82 EPS for the current year.
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
- Five stocks we like better than Sanofi
- Consumer Staples Stocks, Explained
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Best Stocks Under $10.00
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.